Research background · Updated November 1, 2026
Survodutide Research: Publications, Study Types and Background
Short answer
Survodutide. As of November 1, 2026, PubMed indexes 94 records matching Survodutide, the earliest from 2022; 55 were published in 2021–2025 and 50 are reviews. ClinicalTrials.gov lists 29 registered studies matching the compound.
- PubMed records
- 94
- Earliest record
- 2022
- Published 2021–2025
- 55
- Reviews
- 50
- Animal-only studies
- 0
- Registered studies
- 29
Publications per year, 2006–2025
62 records in 2016–2025 against 0 in 2006–2015; the busiest year was 2025, with 35.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 0 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 0 |
| 2011 | 0 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 0 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 21 |
| 2025 | 35 |
Study types
| All PubMed records | 94 |
|---|---|
| Reviews | 5053% |
| Animal studies (no human subjects indexed) | 00% |
| Indexed as clinical trials | 1213% |
| Registered on ClinicalTrials.gov | 29 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 1 of the most-cited and most recent Survodutide papers report, in their own authors’ terms. Each line links the paper it came from.
Liver fat and steatohepatitis
In a phase 2 trial in 293 adults with biopsy-confirmed MASH and fibrosis, survodutide, a dual glucagon and GLP-1 receptor agonist, was superior to placebo for MASH improvement without worsening fibrosis; liver fat fell by at least 30% in 57% to 67% of the survodutide groups against 14% with placebo, and nausea occurred in 66% against 23%.
HumansSanyal AJ 2024The New England journal of medicinePMID 38847460
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 94 of the 94 records. They describe what the literature is about, not what Survodutide does.
- Obesity26 papers
- Glucagon-Like Peptide-1 Receptor Agonists26 papers
- Diabetes Mellitus, Type 220 papers
- Hypoglycemic Agents19 papers
- Fatty Liver11 papers
- Anti-Obesity Agents11 papers
- Glucagon-Like Peptide 17 papers
- Non-alcoholic Fatty Liver Disease7 papers
Key papers
Earliest indexed record
Zimmermann T (2022). Molecular metabolism.
PMID 36356832Most-cited paper · 455 citations
Sanyal AJ (2024). The New England journal of medicine.
PMID 38847460Most-cited #2 · 334 citations
Drucker DJ (2024). Diabetes care.
PMID 38843460Most-cited #3 · 199 citations
le Roux CW (2024). The lancet. Diabetes & endocrinology.
PMID 38330987
Citation counts from NIH iCite, among the 94 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| CAS | 2805997-46-8 |
|---|---|
| Molecular formula | C192H289N47O61 |
| Molecular weight | 4232 g/mol |
| Synonyms | Survodutide, BI-456906, GLXC-27923 |
Identity data from PubChem, retrieved November 1, 2026, on the Survodutide page.
How these numbers were counted
- PubMed search, run November 1, 2026:
survodutide[tiab] OR BI-456906[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
survodutidere-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use Survodutide outside a laboratory.
Wholesale supply
Survodutide, sourced to order for research.
Not held in the listed catalog. Tell us the vial size and the number of vials and we come back with availability, documentation and pricing in writing.
Survodutide research questions
How much research has been published on Survodutide?
PubMed indexes 94 records matching Survodutide (searched November 1, 2026), including 50 reviews and 12 records indexed as clinical trials. 55 were published in the five years 2021–2025.
When was Survodutide first described in the literature?
The earliest PubMed record matching Survodutide is from 2022 (Zimmermann T, Molecular metabolism, PMID 36356832).
What topics does the Survodutide literature cover?
The subject headings PubMed indexers most often marked as a main topic of Survodutide papers are Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
Is Survodutide sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy Survodutide wholesale for research?
We source Survodutide to order rather than stock it. Tell us the vial size and number of vials on WhatsApp or by email and the quote confirms availability, documentation and pricing.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.